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Circulating tumor cells can be detected from the peripheral blood of cancer patients.Their prognostic value has been established in
the last 10 years formetastatic colorectal, breast, and prostate cancer. On the contrary their presence in patients affected by sarcomas
has been poorly investigated. The discovery of EpCAM mRNA expression in different sarcoma cell lines and in a small cohort
of metastatic sarcoma patients supports further investigations on these rare tumors to deepen the importance of CTC isolation.
Although it is not clear whether EpCAM expression might be originally present on tumor sarcoma cells or acquired during the
mesenchymal-epithelial transition, the discovery of EpCAM on circulating sarcoma cells opens a new scenario in CTC detection
in patients affected by a rare mesenchymal tumor.
1. Introduction
Sarcomas are relatively rare but particularly lethal tumors,
with over 5,800 deaths per year in the United States [1],
accounting for about 1% of all adult cancers and approxi-
mately 20% of pediatric solid malignancies [2]. The word
sarcoma represents over fifty subtypes of soft tissuemalignant
tumors of mesenchymal origin. In 2013, the World Health
Organization (WHO) Classification of Tumors of Soft Tissue
and Bone has been published, according to the pathogenesis
of soft tissue and bone tumors related to the histologic and
genetic findings [3, 4].
The diagnosis is performed by hematoxylin and eosin
staining of sections and immunohistochemistry. To date,
radiographic imaging and PET are performed to detect
recurrence and metastasis.
However, different technologies are now available for
molecular characterization of such tumor types, as recently
discussed by Smith et al.; analyses as Polymerase Chain
Reaction (PCR), fluorescent in situ hybridization (FISH),
Real-Time PCR, and next-generation sequencing (NGS) or
the presence of reciprocal chromosomal translocations and
fusion genes may be useful for diagnosis and treatment of
sarcoma patients [5].
Since most soft tissue sarcomas use the hematogenous
dissemination to metastasize to lungs, liver, bones, and
subcutaneous tissue whereas a small percentage may spread
to lymph nodes [6, 7], it is possible to isolate and characterize
circulating tumor cells (CTCs) from whole blood based on
their biological and/or physical properties [8].
Furthermore, CTCs provide through their molecular
evaluation an example of “liquid biopsy” useful for cancer
patient care [9].
2. CTC
The definition of CTC is often associated with tumors of
epithelial origin, even if this definition may include tumor
cells derived from all solid tumors with both epithelial and
mesenchymal origin. CTCs can be detected from the periph-
eral blood of cancer patients; ten years ago the prognostic
significance of CTC isolated by CellSearch System among
patients withmetastatic breast [10–13], colorectal [14, 15], and
prostate cancer [16, 17] has been demonstrated.
Circulating tumor cells referred to carcinomas were first
described in 1869 by Ashworth [18] at autopsy examination,
whereas Engell [19] described for the first time in 1955 the
presence of cancer cells in the bloodstream. Every day a
primary tumor releases an amount of CTCs of 106 for gr of
tumor; the majority of them die and only a small percentage,
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To date, the knowledge derived from years of studies
focused on the role of CTCs comes from the analysis of
epithelial tumors.
The physical and biological characteristics of CTCs have
been employed for their enrichment and isolation; in particu-
lar, their larger size compared to blood cells and the presence,
on their surface, of epithelial antigens allowed new assays for
their isolation and characterization.
3. Carcinoma
The discovery of epithelial cell adhesion molecule (EpCAM)
expression on epithelial cancer cells opened a new era in
the development of several technologies for CTC enrichment
and isolation. To date, due to the presence of new sensitive
assays we can isolate at least single tumor cells between
billions of peripheral blood cells. CellSearch is an EpCAM-
based method, the only one approved by the Food and Drug
Administration (FDA) for CTC enumeration. CellSearch
assay was analytically validated by Allard et al. [21], and it
is recognized as a very sensitive, accurate, and reproducible
method [21]. The CellSearch kits used for epithelial CTC
capture contain ferrofluids labeled with EpCAM, the stain-
ing reagents, 4󸀠,6-diamidino-2-phenylindole, dihydrochlo-
ride (DAPI), CD45-Allophycocyan (CD45-APC), and cytok-
eratin 8, 18, and 19 Phycoerythrin (CK-PE) [22]. According
to CellSearch manufacturer’s instructions, a CTC is charac-
terized by positivity for EpCAM, cytokeratins (CKs), nuclear
dye (DAPI), and negativity for CD45 [23]. CTC enumeration,
detected in 7.5mLof blood, has prognostic value inmetastatic
breast [10–13], prostate [16, 17], and colon cancer patients [14,
15]. For metastatic patients with breast and prostate cancer
with a count of CTC fewer than five in a blood sample of
7.5mL higher survival was observed, as well as for metastatic
colorectal cancer patients with a CTC value of 3 or fewer for
7.5mL of blood. The presence and prognostic significance of
CTC in blood ofmetastatic patients with small and non-small
cell lung cancer [24, 25], stomach cancer [26], pancreatic
cancer [27], ovarian cancer [28], and both advanced [29] and
nonmuscle invasive bladder cancer [30, 31] have been also
demonstrated.
In order to isolate CTC from cancer patients affected by
carcinoma, studies have advanced from Reverse Transcrip-
tase-Polymerase Chain Reaction- (RT-PCR-) based methods
to immunomagnetic enrichment of tumor cells exploiting
the presence of molecular markers as EpCAM on the CTC
surface.
Immunomagnetic separation (IMS) may be achieved
using Dynabeads, through enrichment or depletion of leuko-
cytes with magnetic beads coated anti-CD45 antibody [32,
33]. For the enrichment beads coated with antibodies against
specific antigens present on the cell surface, especially
towards the human EpCAM or antibody against tumor
specific markers can be used.
Among the molecular-based techniques developed,
AdnaTest is a series of commercially available assays that com-
bines an immunomagnetic enrichment of tumor cells fol-
lowed by subsequent multiplex RT-PCR [34].
To date, microfluidic devices for CTC capture called
CTC-Chip are also available; in recent years several devices
have been created, both EpCAM and non-EpCAM-based, all
able to provide living CTCs, suitable for molecular analysis
and characterization [35–37].
A simple and versatile assay forCTC capture and genomic
or proteomic analysis is ISET. Isolation by size of tumor cells
(ISET) is a marker-independent assay for the isolation of
intact CTCs from blood through direct filtration, using poly-
carbonate membrane with 8 𝜇m diameter cylindrical pores
taking advantage of the larger size of tumor cells compared
with leukocytes. CTCs are then identified by cytomorphology
and can be characterized by immunofluorescence (IF) assays
but their enumeration is hard to be obtained [38, 39].
4. EMT
The epithelial-mesenchymal transition (EMT) has been
widely investigated in carcinomas. Being characterized by
loss of epithelial markers and acquisition of mesenchymal
features, it allows carcinoma cells to escape from their struc-
tural confines, increasing their mobility and invasiveness,
to enter into the bloodstream and to adhere and develop
into distant metastases [40, 41]. Cells that undergo EMT
are different from the conventional concept of CTCs: they
express low or null EpCAM expression and might be missed
by EpCAM-based approach [42–44]. Progression of solid
tumors involves spatial and temporal occurrences of EMT,
whereby tumor cells acquire a more invasive and metastatic
phenotype. Subsequently, the disseminated mesenchymal
tumor cells undergo the mesenchymal-to-epithelial transi-
tion (MET), at the site of metastases, which often recapitulate
the pathology of their corresponding primary tumors. EMT
is considered a reversible process of switch from an epithelial
to a mesenchymal cellular phenotype.This transition leads to
downregulation of epithelial markers as CKs and E-cadherin
and to upregulation ofmesenchymal biomarkers as vimentin,
fibronectin, and N-cadherin [40, 45, 46]. EMT enhances
migratory and invasive properties of cancer cells and their
survival in the bloodstream. The following MET process is
responsible for CTC extravasation and colonization in distant
organs lesion which is expressed with metastatic disease [47–
49].
5. Carcinosarcoma
Carcinosarcomas are rare biphenotypic tumors with char-
acteristics of epithelial as well as sarcoma tumor cells [50,
51]. The hypothesis that stem/progenitor cells can play a
role as common precursors for tumors of carcino/sarcoma
phenotype such as squamomelanocytic tumors [52] and
perhaps carcinosarcomas has been suggested.
Carcinosarcomawas originally described in 1972 byDaw-
son [53] andmore recently studies on lung, ovarian, and uter-
ine carcinosarcomas were performed. Paniz Mondolfi et al.
[51] recently published a study performed on a primary
cutaneous carcinosarcoma and demonstrated an immunore-
activity for EpCAM in both mesenchymal and epithelial
components, suggesting that EpCAM might represent a
potential target for cutaneous carcinosarcoma.
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The presence, in carcinosarcoma tumors, of sarcomatous
and epithelial tumor components led to further studies
focused on the presence of epithelial markers on sarcoma
cells.
6. Sarcoma
Few studies have been performed on sarcoma-derived CTCs,
perhaps because sarcomas are considered relatively rare
neoplasms despite their poor prognosis.
More recently, EpCAM-positive circulating cells were
detected in soft tissue sarcoma patients and a genomic
meta-analysis of gene expression profiles demonstrated that
EpCAM mRNA is expressed in different sarcoma cell lines.
Immunohistochemical staining revealed EpCAM protein
expression in a subset of angiosarcomas and leiomyosarco-
mas and in all the osteosarcomas analyzed; in addition, a
negative prognostic marker for leiomyosarcoma patients has
been suggested [54].
The presence of EpCAM on CTC from metastatic sar-
coma patients was shown by Vincenzi et al. using the
CellSearch System. They enrolled twenty-three patients with
metastatic STSs at first, second, and third line of chemother-
apy and CTCs were detected in 43% of enrolled patients with
a CTC count range of 0–4 cells/7.5mL [8].
In a recent review by Chang et al. [55], CTC detection
in sarcoma has been underlined; the majority of studies
were performed on Ewing’s sarcoma by RT-PCR analysis for
the research of the fusion gene product associated with the
disease EWS-FLI-1 and EWS-ERG marker. Data regarding
the prognostic significance of CTC isolation in sarcoma,
although poor, show a correlation betweenCTCpresence and
poor outcome or disease progression [56].
Cancer cells show a larger size compared to leukocytes
and this physical characteristic was used to isolate and
characterize CTC from sarcoma tumors for the first time by
Chinen et al. [56]. In this study, which was performed on
eleven patients with metastatic/recurrent or locally advanced
soft tissue sarcomas, positivity for CTC detection has been
shown for all patients enrolled, with a recovery rate of CTC
from two to 48 per 8mL of blood. For CTC characterization
authors used anti-CD45 (specific marker for WBCs), anti-
vimentin (mesenchymal-related marker), and anti-Pan CK
(epithelial-related marker) antibodies, to discriminate CTCs
from leucocytes in the immunocytochemistry assay.
Vimentin is considered the main protein associated with
the EMT process and consequently with increased invasive-
ness, chemoresistance, and metastatic phenotype of these
cells.The presence of vimentin on the surface of cancer cells is
considered a sign of a mesenchymal phenotype of CTCs [57].
Although detection of cell-surface vimentin in cancer
cells has been demonstrated in different studies [58, 59], its
role as a biomarker by using a monoclonal antibody 84-1
for detecting CTC from blood of cancer patients affected by
carcinoma as well as sarcoma has been established [57].
7. MET
If it is true that EMT has been suggested to promote
the growth of epithelial tumor cells at distant sites during
metastasis, the inverse process MET might be considered as
an efficient process for the dissemination of sarcoma cells.
Several types of sarcomas, including synovial sarcoma, lei-
omyosarcoma, chondrosarcoma, osteosarcoma, chordoma,
epithelioid sarcoma, and ES/PNET, have been reported to
show epithelial differentiation on the basis of detection of
epithelial markers including E-cadherin. Recent findings
reveal that mesenchymal-epithelial transition may exist in
sarcomas, leading to a switch towards an epithelial pheno-
type. Accumulating evidences suggest that deeper investi-
gation and understanding of MET in sarcomas would shed
light on the pathogenesis of sarcomas and might lead to
identification of potential clinical biomarkers for prognosis
and targets for sarcoma therapeutics.
In this view, EMT/MET processes may be considered the
link between carcinoma and sarcoma tumors, two distinct
and reversible regulated mechanisms employed by tumoral
cells, both responsible for developing distant metastases.
8. Discussion and Conclusion
Although it is not clear whether tumor sarcoma cells con-
stitutively express EpCAM or alternatively they acquire it
during the mesenchymal-epithelial transition, the discovery
of EpCAM on circulating sarcoma cells opens a new scenario
in CTC detection in patients affected by rare tumors.
CellSearch System offers the possibility to study the
expression of an additional marker of interest by the use of
the fourth channel. To date, this channel has been used to
study the apoptotic status ofCTCs integrating the systemwith
a monoclonal antibody, anti-M30 [60], anti Bcl-2 [61], and
anti-M65 [62].
CellSearch, an EpCAM-based assay, can be integrated
with an anti-vimentin antibody in its fourth channel, to dis-
criminate sarcoma circulating cells positive for EpCAM and
vimentin and negative for CD45, from leucocytes positive for
CD45.
Vimentin is considered a specificmarker ofmesenchymal
derivation or differentiation and its expression in sarcoma
circulating cells, presumably undergoingMET, seems contra-
dictory and requires further studies.
Satelli et al. [63] developed an anti-vimentin antibody
able to discriminate the expression of cell-surface vimentin,
mainly associated with cancer cells, from the intracellular
vimentin expressed by most white blood cells in order to
exclude bias to use this protein as a CTC marker.
Using the CellSearch System this bias could be excluded:
the choice of intracellular or extracellular antibody is indif-
ferent because we may discriminate the false positive results
by the leucocytes positivity for CD45.
More than ten years ago, CTC enumeration was validated
as prognostic biomarker in metastatic breast cancer using the
US Food and Drug Administration- (FDA-) cleared system
CellSearch (Janssen Diagnostics, LLC, Raritan, NJ, USA); we
believe that studies on biomarkers in sarcoma patients may
quickly evolve in the next future through CTC enumeration
as well as phenotypic and genotypic characterization.
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